BACKGROUND: MicroRNAs (miRNAs) are emerging as promising molecules in the diagnosis, prognosis and treatment of urological tumours. Recently, our group performed two independent studies highlighting that miR-210-3p may be a useful biomarker not only for diagnosis but also for post-surgery clear cell Renal Cell Carcinoma (ccRCC) management. OBJECTIVE: The aim of this study is to further explore the effectiveness of miRNA as non-invasive biomarker for clinical outcomes and ccRCC response to the treatment. METHODS: We analyzed miR-210-3p levels in neoplastic and healthy tissue and in urine specimens collected at surgery and during follow-up of 21 ccRCC patients by RTqPCR. RESULTS: Firstly, we confirmed that the expression of miR-210-3p was upregulated in tumor tissues and in urine samples of analyzed cohort. Of note is that miR-210-3p expression was significantly reduced in urine samples from disease-free patients during follow-up (from 3 to 12 months) compared to the baseline levels observed at the time of surgery. In a small subgroup of patients presenting metastatic progression (such as bone, intestinal or lung metastasis), the urine levels of miR-210-3p correlated with responsiveness to the therapy. CONCLUSIONS: This pilot study highlights the relevance of secreted miR-210-3p as powerful non-invasive prognostic and predictive biomarker for the evaluation of clinical outcomes and treatment response during ccRCC follow up.

Emerging role of secreted miR-210-3p as potential biomarker for clear cell renal cell carcinoma metastasis / Petrozza, Vincenzo; Costantini, Manuela; Tito, Claudia; Giammusso, Laura Maria; Sorrentino, Veronica; Cacciotti, Jessica; Porta, Natale; Iaiza, Alessia; Pastore, Antonio Luigi; Di Carlo, Angelina; Simone, Giuseppe; Carbone, Antonio; Gallucci, Michele; Fazi, Francesco. - In: DISEASE MARKERS. SECTION A, CANCER BIOMARKERS. - ISSN 1574-0153. - 27:2(2020), pp. 181-188. [10.3233/CBM-190242]

Emerging role of secreted miR-210-3p as potential biomarker for clear cell renal cell carcinoma metastasis

Petrozza, Vincenzo;Tito, Claudia;Porta, Natale;Iaiza, Alessia;Pastore, Antonio Luigi;Di Carlo, Angelina;Carbone, Antonio;Gallucci, Michele;Fazi, Francesco
2020

Abstract

BACKGROUND: MicroRNAs (miRNAs) are emerging as promising molecules in the diagnosis, prognosis and treatment of urological tumours. Recently, our group performed two independent studies highlighting that miR-210-3p may be a useful biomarker not only for diagnosis but also for post-surgery clear cell Renal Cell Carcinoma (ccRCC) management. OBJECTIVE: The aim of this study is to further explore the effectiveness of miRNA as non-invasive biomarker for clinical outcomes and ccRCC response to the treatment. METHODS: We analyzed miR-210-3p levels in neoplastic and healthy tissue and in urine specimens collected at surgery and during follow-up of 21 ccRCC patients by RTqPCR. RESULTS: Firstly, we confirmed that the expression of miR-210-3p was upregulated in tumor tissues and in urine samples of analyzed cohort. Of note is that miR-210-3p expression was significantly reduced in urine samples from disease-free patients during follow-up (from 3 to 12 months) compared to the baseline levels observed at the time of surgery. In a small subgroup of patients presenting metastatic progression (such as bone, intestinal or lung metastasis), the urine levels of miR-210-3p correlated with responsiveness to the therapy. CONCLUSIONS: This pilot study highlights the relevance of secreted miR-210-3p as powerful non-invasive prognostic and predictive biomarker for the evaluation of clinical outcomes and treatment response during ccRCC follow up.
2020
cancer biomarkers; liquid biopsy; ccRCC; m iR-210; metastasis; miRNA; microRNA
01 Pubblicazione su rivista::01a Articolo in rivista
Emerging role of secreted miR-210-3p as potential biomarker for clear cell renal cell carcinoma metastasis / Petrozza, Vincenzo; Costantini, Manuela; Tito, Claudia; Giammusso, Laura Maria; Sorrentino, Veronica; Cacciotti, Jessica; Porta, Natale; Iaiza, Alessia; Pastore, Antonio Luigi; Di Carlo, Angelina; Simone, Giuseppe; Carbone, Antonio; Gallucci, Michele; Fazi, Francesco. - In: DISEASE MARKERS. SECTION A, CANCER BIOMARKERS. - ISSN 1574-0153. - 27:2(2020), pp. 181-188. [10.3233/CBM-190242]
File allegati a questo prodotto
File Dimensione Formato  
Petrozza_Emerging_2020.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.69 MB
Formato Adobe PDF
1.69 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1340650
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 17
social impact